Immuno-Oncology | Specialty

Dr. Burtness on Immunotherapy and Radioresistance in Head and Neck Cancer

July 19th 2017

Barbara Burtness, MD, professor of Medicine, Yale Cancer Center, discusses immunotherapy in patients with head and neck cancer who have radioresistance.

Dr. Powles on Bevacizumab Plus Atezolizumab in Kidney Cancer

July 19th 2017

Thomas Powles, MD, Barts Cancer Institute, discusses the combination of bevacizumab (Avastin) and atezolizumab (Tecentriq) versus single-agent atezolizumab versus sunitinib (Sutent), which was studied in the randomized, phase II IMmotion150 trial for patients with metastatic renal cell carcinoma (RCC).

Dr. Apolo on the Safety of Nivolumab Plus Cabozantinib in Urothelial Carcinoma

July 19th 2017

Andrea Apolo, MD, medical oncologist, chief of the bladder cancer section of the Genitourinary Malignancies Branch, National Cancer Institute, discusses the adverse events of the combination of nivolumab (Opdivo) and cabozantinib (Cabometyx) for patients with urothelial carcinoma.

Modeling T-Cell Trafficking to Increase the Likelihood of Radiation-Induced Abscopal Effects

July 19th 2017

The combination of radiation and immunotherapy is currently enjoying unprecedented attention as a treatment strategy for patients with metastatic cancer.

Dr. Bauml Discusses Immunotherapy in Head and Neck Cancer

July 19th 2017

Joshua Bauml, MD, assistant professor, Perelman School of Medicine, University of Pennsylvania, discusses immunotherapy in head and neck cancer.

Dr. Cohen Discusses Immunotherapy Combinations in Head and Neck Cancer

July 18th 2017

Ezra Cohen, MD, associate director, Moores Cancer Center at the University of California, San Diego, discusses immunotherapy combinations in head and neck cancer.

Unmet Needs in Kidney Cancer

July 17th 2017

Kidney Cancer: Non-Clear Cell Histology

July 17th 2017

Kidney Cancer: Vaccine-Based Approaches

July 17th 2017

Novel Combinations in Kidney Cancer

July 17th 2017

Anti-VEGF/Immunotherapy Combinations in Kidney Cancer

July 17th 2017

New Strategies in Kidney Cancer

July 17th 2017

Immunotherapy in Kidney Cancer

July 17th 2017

Practical Experience With Lenvatinib/Everolimus in RCC

July 17th 2017

mTOR/TKI Combination Therapy in Kidney Cancer

July 17th 2017

Role of mTOR Inhibition in Kidney Cancer

July 17th 2017

Frontline TKI Strategies in Kidney Cancer

July 17th 2017

Kidney Cancer: Continuing to Improve Survival

July 17th 2017

Understanding the Biology of Kidney Cancer

July 17th 2017

Experts Discuss Immunotherapy's Evolution in Bladder Cancer

July 15th 2017

The explosion of new checkpoint immunotherapy drugs has changed the paradigm of care for patients with urothelial carcinoma, the most common form of bladder cancer.